Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
401-420 of 2,120 trials

Sickle Cell Pain Relief: Intranasal Sufentanil Study

We are investigating whether a new nasal spray for pain relief helps children with severe sickle cell pain crises feel better faster than standard treatments. This study aims to improve pain management in pediatric emergency care.

Vaso-Occlusive Crisis>2 yearsConfirmation phase (III)Investigational MedicinesHematologyInternal MedicinePediatrics

Sotatercept for Children with Pulmonary Artery Hypertension

We are studying the safety and effects of sotatercept in children aged 1 to under 18 with pulmonary artery hypertension. This research aims to improve treatment options for young patients already receiving standard care.

Pulmonary Arterial Hypertension3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteCardiologyPulmonology

Cutaneous Lupus Erythematosus: Litifilimab Injections

We are studying the long-term safety and effects of Litifilimab injections for adults with active cutaneous lupus erythematosus who have not responded to other treatments. This research aims to see if it can improve symptoms and overall quality of life.

Skin Lupus (Cutaneous Lupus Erythematosus)>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementDermatologyRheumatology

Bomedemstat vs Best Available Therapy for Essential Thrombocythemia

We are studying a new treatment for patients with essential thrombocythemia who haven't responded to hydroxyurea. The trial aims to see if bomedemstat is safer and more effective than current therapies.

Essential Thrombocythemia>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematology

Pediatric Cancer: Crizotinib Treatment Study

We are testing the safety and effectiveness of crizotinib, alone and with temsirolimus, for children with ALK, ROS1, or MET positive cancers. This study aims to find the best dose and understand how well these treatments work.

NeuroblastomaAnaplastic Large Cell LymphomaInflammatory Myofibroblastic Tumors6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Dopaminergic Pathway Changes in Comatose Patients with Traumatic Brain Injury

We are studying how traumatic brain injuries affect dopamine pathways in patients who are in a coma. This research may help us understand recovery patterns and improve future treatments.

Traumatic Brain Injury>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesNeurologyOtolaryngology

Advanced Thyroid Cancer: Sacituzumab Govitecan Study

We are testing a new drug for patients with advanced differentiated and anaplastic thyroid neoplasms. The goal is to see if it can effectively control the disease and improve patient outcomes.

Thyroid Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyOncology

Progressive Pulmonary Fibrosis: Inhaled Treprostinil Study

We are investigating whether inhaled treprostinil can improve lung function in people with progressive pulmonary fibrosis. The study will also assess its safety and impact on overall health.

Progressive Pulmonary Fibrosis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesPulmonology

Non-Transfusion-Dependent Thalassemia: Luspatercept Treatment

We are studying whether luspatercept can improve brain oxygen levels and blood flow in patients with non-transfusion-dependent thalassemia. The trial also looks at its effects on cognitive function and heart health.

Non-transfusion Dependent Beta-Thalassemia6-12 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesHematologyNeurology

Lung Cancer Treatment: MK-2870 vs. Chemotherapy

We are studying a new drug, MK-2870, for patients with advanced lung cancer who have already tried other treatments. The goal is to see if it works better than standard chemotherapy options.

Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)Investigational MedicinesOncology

Prostate Cancer: 177Lu-PSMA Treatment Study

We are studying a new treatment for men with high-risk prostate cancer after initial therapies. The trial aims to see if this treatment helps prevent cancer from coming back and improves quality of life.

Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Dobutamine for Very Preterm Infants with Low Blood Flow

We are studying the lowest effective dose of dobutamine to help improve blood flow in very preterm infants. The trial also looks at how well the treatment works and its safety during the first few days after birth.

Neonates with Haemodynamic Insufficiency>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCardiologyPediatrics

Prostate Cancer Recurrence: PSMA PET/CT vs. Salvage Radiotherapy

We are comparing a personalized treatment approach using PSMA PET/CT imaging with standard salvage radiotherapy for patients whose prostate cancer has returned after surgery. The goal is to see which method better helps manage their condition and improves quality of life.

Recurrent Prostate Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Breast Cancer: MK-2870 with or without Pembrolizumab

We are comparing a new treatment for advanced breast cancer that can't be surgically removed to standard chemotherapy. This study aims to see if the new treatment improves outcomes for patients.

Hormone Receptor Positive Breast Cancer>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesOncology

Non-Small Cell Lung Cancer: V940 and Pembrolizumab Study

We are testing a new treatment combining V940 with pembrolizumab for patients with resected stage II to IIIB non-small cell lung cancer. The study aims to see if this combination improves survival and quality of life compared to a placebo.

Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementOncology

Hematologic Malignancies: MK-1026 Treatment Study

We are evaluating a new treatment for patients with blood cancers to see if it is safe and effective in reducing symptoms. This study focuses on various types of hematologic malignancies, including CLL and MCL.

Blood CancerEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Triple-Negative Breast Cancer: MK-2870 with Pembrolizumab

We are studying a new treatment combining MK-2870 and pembrolizumab for people with triple-negative breast cancer who had surgery but did not respond completely. The trial aims to see if this combination works better than standard treatment options.

Triple Negative Breast Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Cervical Cancer: Surgery Plus Therapy Study

We are investigating whether additional therapy after surgery helps patients with early-stage, intermediate-risk cervical cancer stay cancer-free. This study compares outcomes with and without further treatment.

Early-Stage Cervical Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Advanced Solid Tumors: AZD9574 Treatment Study

We are studying the safety and early effectiveness of AZD9574, both alone and with other cancer therapies, for patients with advanced solid tumors. This research aims to improve treatment options for those facing these challenging conditions.

Advanced Ovarian, Breast, Pancreatic, or Prostate CancerHER2+ Metastatic Solid TumorsAdvanced Unresectable or Metastatic Solid TumorsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Surgical Site Infection Prevention: Linezolid vs. Vancomycin

We are studying whether linezolid is as effective as vancomycin in preventing infections after surgery. This trial includes various surgeries and looks at infection rates and patient experiences.

Surgical Antibiotic Prophylaxis>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesOrthopedics and Traumatology